Azer S A, Stacey N H
Toxicology Unit, National Institute of Occupational Health and Safety, University of Sydney, New South Wales, Australia.
J Gastroenterol Hepatol. 1996 Apr;11(4):396-407. doi: 10.1111/j.1440-1746.1996.tb01390.x.
Hepatic sinusoidal uptake of bile acids is mediated by defined carrier proteins against unfavourable concentration and electrical gradients. Putative carrier proteins have been identified using bile acid photoaffinity labels and more recently using immunological probes, such as monoclonal antibodies. At the sinusoidal domain, proteins with molecular weights of 49 and 54 kDa have been shown to be carriers for bile acid transport. The 49 kDa protein has been associated with the Na(+)-dependent uptake of conjugated bile acids, while the 54 kDa carrier has been involved in the Na(+)-independent bile acid uptake process. Within the hepatocyte, cytosolic proteins, such as the glutathione S-transferase (also designated the Y protein), the Y binders and the fatty acid binding proteins, are able to bind bile acids and possibly facilitate their movement to the canalicular domain. At the canalicular domain a 100 kDa carrier protein has been isolated and it has been shown by several laboratories that this particular protein is concerned with canalicular bile acid transport. The system is ATP-dependent and follows Michaelis-Menten kinetics. Interference with bile acid transport has been demonstrated by several chemicals. The mechanisms by which these chemicals inhibit bile acid transport may explain the apparent cholestatic properties observed in patients and experimental animals treated with these agents. Several studies have shown that Na+/K(+)-ATPase activity is markedly decreased in cholestasis induced by ethinyloestradiol, taurolithocholate and chlorpromazine. However, other types of interference have been described and the cholestatic effects may be the result of several mechanisms. Cholestasis is associated with several adaptive changes that may be responsible for the accumulation of bile acids and other cholephilic compounds in the blood of these patients. It may be speculated that the nature of these changes is to protect liver parenchymal cells from an accumulation of bile acids to toxic levels. However, more detailed quantitative experiments are necessary to answer questions with regard to the significance of these changes and the effect of various hepatobiliary disorders in modifying these mechanisms. It is expected that the mechanisms by which bile acid transport is regulated and efforts to understand the molecular basis for these processes will be among the areas of future research.
肝窦对胆汁酸的摄取是由特定的载体蛋白介导的,以对抗不利的浓度和电势梯度。已使用胆汁酸光亲和标记物并在最近使用免疫探针(如单克隆抗体)鉴定出了假定的载体蛋白。在肝窦域,分子量为49 kDa和54 kDa的蛋白质已被证明是胆汁酸转运的载体。49 kDa的蛋白质与结合型胆汁酸的钠依赖性摄取有关,而54 kDa的载体参与了非钠依赖性胆汁酸摄取过程。在肝细胞内,胞质蛋白,如谷胱甘肽S-转移酶(也称为Y蛋白)、Y结合蛋白和脂肪酸结合蛋白,能够结合胆汁酸,并可能促进它们向胆小管域的移动。在胆小管域,已分离出一种100 kDa的载体蛋白,几个实验室已表明这种特定的蛋白质与胆小管胆汁酸转运有关。该系统依赖ATP,并遵循米氏动力学。几种化学物质已证明会干扰胆汁酸转运。这些化学物质抑制胆汁酸转运的机制可能解释了在用这些药物治疗的患者和实验动物中观察到的明显胆汁淤积特性。几项研究表明,在乙炔雌二醇、牛磺石胆酸和氯丙嗪诱导的胆汁淤积中,Na+/K(+)-ATP酶活性显著降低。然而,已描述了其他类型的干扰,胆汁淤积效应可能是多种机制的结果。胆汁淤积与几种适应性变化有关,这些变化可能是这些患者血液中胆汁酸和其他亲胆化合物积累的原因。可以推测,这些变化的本质是保护肝实质细胞免受胆汁酸积累至毒性水平的影响。然而,需要更详细的定量实验来回答关于这些变化的意义以及各种肝胆疾病对这些机制的影响的问题。预计胆汁酸转运的调节机制以及了解这些过程分子基础的努力将成为未来研究的领域。